Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maraviroc in HIV-related Kaposi's Sarcoma
NCT01276236Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Mar 2011
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of maraviroc in Kaposi's sarcoma (KS), sponsored by University of California, San Francisco. Primary endpoint: Number of Participants With a Decrease in Kaposi's Sarcoma Total Surface Area at 96 weeks. Started Mar 2011; status: completed.
02
Drugs
maraviroc
03
Conditions
Kaposi's sarcoma (KS)
Beyond the preview
Go deeper on NCT01276236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01276236.